In short
Understanding how malignant gliomas are diagnosed is essential for anyone facing this serious brain tumor, as the right tests can guide treatment decisions and help doctors plan the best path forward during a challenging time.
Key points
- Modern diagnosis of malignant gliomas now relies on genetic and molecular testing, not just what tumor cells look like under a microscope, fundamentally changing how these tumors are classified and treated.
- MRI with contrast dye is the gold standard imaging test for malignant gliomas because it provides the most detailed pictures of soft brain tissue and tumor boundaries.
- The MGMT methylation test can predict whether chemotherapy will be effective, giving patients and doctors important information for treatment planning.
- Malignant gliomas peak between ages 45 and 64 depending on type, are 40% more common in men, and occur twice as often in white populations, though most cases have no clear identifiable cause.
- Clinical trials require specific diagnostic tests beyond standard diagnosis, including detailed molecular profiling, recent protocol-specific imaging, and comprehensive health assessments.
- The 2021 World Health Organization classification system incorporates molecular markers like IDH gene status to more accurately categorize brain tumors and guide treatment decisions.
- Neurological examinations can provide early clues about tumor location, as problems on one side of the body often indicate a tumor on the opposite side of the brain.
- Tissue obtained during surgery or biopsy undergoes multiple types of analysis including microscopic examination, genetic testing, and molecular profiling to create a complete diagnostic picture.
Introduction: Who Should Seek Diagnostic Testing
Malignant gliomas are rapidly progressive brain tumors that require prompt medical attention. Anyone experiencing persistent or worsening symptoms should seek diagnostic evaluation from a healthcare provider as soon as possible. These tumors can affect people at different ages, with the peak incidence occurring between the fifth and sixth decades of life, though they can develop in younger adults as well.
Diagnostic testing is advisable when a person experiences certain warning signs that suggest something may be wrong with their brain function. Common symptoms that should prompt a medical evaluation include persistent headaches that are particularly severe in the morning, sudden changes in vision such as blurred or double vision, seizures that occur for the first time, weakness or numbness on one side of the body, difficulty with balance or coordination, personality changes or mood swings, problems with memory or thinking, and unexplained nausea and vomiting.
These symptoms develop because the tumor grows and presses on brain tissue, affecting the specific functions controlled by that area of the brain. For example, a tumor in the area controlling movement might cause weakness, while one affecting vision areas could lead to sight problems. The symptoms can develop gradually over time or appear more suddenly, depending on how quickly the tumor is growing.
It's important to understand that experiencing one or more of these symptoms doesn't automatically mean a person has a malignant glioma. Many other conditions can cause similar symptoms. However, these warning signs indicate that something needs medical investigation, and early diagnosis can make a significant difference in treatment options and outcomes.
Classic Diagnostic Methods for Identifying Malignant Gliomas
The diagnostic process for malignant gliomas involves several different types of tests and examinations. Each test provides specific information that helps doctors understand what is happening inside the brain and distinguish malignant gliomas from other conditions.
Neurological Examination
The first step in diagnosis typically involves a comprehensive neurological examination, which is a physical assessment of how well the brain and nervous system are functioning. During this examination, the doctor checks various aspects of neurological function including vision, hearing, balance, coordination, strength, and reflexes. If difficulties are detected with certain tasks, this can provide clues about where in the brain a problem might be located.
For instance, if a patient has trouble with coordination on one side of their body, this might suggest the tumor is located in the opposite side of the brain, since each side of the brain controls the opposite side of the body. Problems with speech might indicate involvement of specific language areas. This examination helps doctors decide which additional tests are needed and what areas to focus on during imaging.
Imaging Tests: Seeing Inside the Brain
Imaging tests create detailed pictures of the brain and are essential for diagnosing malignant gliomas. The most commonly used imaging test is magnetic resonance imaging, known as MRI. An MRI uses powerful magnets and radio waves to create very detailed images of the brain's soft tissues. This test is particularly good at showing the size, location, and extent of brain tumors.
During an MRI scan, patients lie still inside a large tube-shaped machine while it takes pictures. The test is painless, though some people find the enclosed space uncomfortable. Often, a contrast dye is injected into a vein before or during the scan. This dye helps create clearer, more detailed pictures by highlighting certain areas of the brain, making it easier to see the tumor and its boundaries.
Another imaging option is a computed tomography scan, or CT scan, which uses X-rays to create cross-sectional images of the brain. While CT scans are faster and more readily available than MRI, they don't show as much detail of soft brain tissue. However, they can still be useful, particularly in emergency situations or when MRI isn't available or possible for a patient.
In some cases, doctors may also use positron emission tomography, or PET scan, which shows how tissues and organs are functioning rather than just their structure. This type of scan can help distinguish between active tumor tissue and scar tissue or areas affected by previous treatment.
Biopsy and Tissue Analysis
While imaging tests can show that a tumor is present, a biopsy is usually necessary to definitively determine what type of tumor it is and whether it is malignant. A biopsy involves removing a small sample of the tumor tissue so it can be examined under a microscope by specialized doctors called pathologists.
There are different ways to obtain tissue for biopsy. Sometimes a procedure called stereotactic needle biopsy is performed before surgery. During this procedure, imaging tests guide a thin needle through a small hole in the skull to the tumor location. The needle removes a tiny sample of tissue, which is then sent to the laboratory for analysis. This type of biopsy is typically used when surgery to remove the tumor isn't immediately planned or isn't possible.
In many cases, the tissue sample is obtained during surgery to remove the tumor. In this situation, a separate biopsy procedure beforehand may not be necessary. The surgeon removes tumor tissue, and portions are sent for immediate and detailed analysis.
Advanced Laboratory Testing of Tumor Cells
Once tissue is obtained, pathologists perform detailed examinations to classify the tumor accurately. They look at how the cells appear under a microscope, checking whether they look similar to normal brain cells or very abnormal. The more abnormal the cells appear, the higher the grade and the more aggressive the tumor is likely to be.
Modern diagnosis goes beyond just looking at cell appearance. Pathologists now perform molecular testing to look for specific genetic changes and proteins in the tumor cells. These tests provide important information about how the tumor might behave and respond to treatment.
One important test looks for changes in a gene called IDH, which stands for isocitrate dehydrogenase. Tumors can be classified as either IDH mutant, meaning they have changes in this gene, or IDH wildtype, meaning the gene is unchanged. This distinction helps predict how the tumor will behave and guides treatment decisions. Malignant gliomas that are IDH wildtype, particularly glioblastomas, tend to be more aggressive.
Another important molecular test is the MGMT methylation test. MGMT is a protein that can repair damage to tumor cells caused by chemotherapy, essentially preventing the treatment from working effectively. The test determines whether the MGMT gene is turned off through a process called methylation. If it is turned off, chemotherapy is more likely to be effective because the tumor cells cannot repair themselves as easily. If MGMT levels are high and the gene is not methylated, chemotherapy may be less effective.
Doctors also look for other genetic markers and chromosome changes that help classify the tumor and predict its behavior. For example, testing may reveal changes in genes like EGFR or TERT, or alterations in specific chromosomes. All this information together helps create a complete picture of the specific type of malignant glioma a patient has.
Grading the Tumor
Malignant gliomas are graded on a scale to indicate how quickly they are likely to grow and spread. The World Health Organization, or WHO, classification system groups brain tumors into grades ranging from grade 1, which are the slowest growing, to grade 4, which are the most aggressive and fastest growing. Malignant gliomas are typically grade 3 or grade 4 tumors.
Grade 3 malignant gliomas include anaplastic astrocytomas, anaplastic oligodendrogliomas, and mixed anaplastic oligoastrocytomas. These tumors have cells that divide rapidly and don't look or behave like normal cells. Grade 4 gliomas include glioblastomas, which are the most aggressive type. All glioblastomas are automatically classified as grade 4 because they grow very quickly and invade surrounding healthy brain tissue.
The grade is determined by examining several features of the tumor cells, including how fast they are dividing, how abnormal they look compared to normal cells, whether there is tissue death within the tumor (called necrosis), and whether new blood vessels are forming to supply the tumor. These features, combined with molecular markers, help doctors predict how the tumor will behave and what treatments might work best.
Diagnostic Tests Used for Clinical Trial Qualification
When patients with malignant gliomas consider participating in clinical trials, additional diagnostic tests beyond standard diagnosis may be required. Clinical trials are research studies that test new treatments, and they have specific criteria about which patients can participate. These criteria ensure that the study results are meaningful and that participants are likely to benefit from or tolerate the experimental treatment.
Detailed Molecular and Genetic Testing
Clinical trials often require comprehensive molecular profiling of the tumor. This goes beyond the basic genetic tests performed for diagnosis and treatment planning. Researchers need detailed information about specific genetic mutations, protein expression patterns, and other molecular characteristics of the tumor cells. This information helps match patients to trials testing treatments targeted at specific genetic or molecular features.
For example, some clinical trials specifically enroll patients whose tumors have certain genetic mutations that the experimental treatment is designed to target. The trial may require documentation of IDH gene status, EGFR amplification, BRAF mutations, or other specific genetic alterations. Without this molecular information, patients cannot be considered for these targeted therapy trials.
Performance Status Assessment
Clinical trials typically have requirements about how well patients can function in daily life. Healthcare providers use standardized scales to assess performance status, which measures how capable a person is of caring for themselves, working, and being active. These assessments help ensure that patients are healthy enough to tolerate the experimental treatment being studied.
Patients with better performance status, meaning they can carry out most normal activities with little assistance, are often preferred candidates for clinical trials. This is because they are more likely to complete the trial, tolerate the treatment, and show whether the experimental therapy is truly beneficial.
Imaging Requirements for Enrollment and Monitoring
Clinical trials have specific requirements for imaging tests both before enrollment and during the study period. Most trials require a recent MRI scan performed within a certain timeframe before enrollment, often within two to four weeks. This baseline scan establishes the size and characteristics of the tumor before the experimental treatment begins.
The imaging must typically be performed according to specific protocols, meaning the scans are done in standardized ways that allow researchers to accurately compare results across all patients in the trial. This might include requirements about the type of MRI sequences used, whether contrast dye was given, and the timing of the scans. Follow-up scans during the trial are also performed on a specific schedule to monitor how the tumor responds to treatment.
Tissue Availability for Research
Many clinical trials require that tumor tissue be available for additional research testing. This might mean that tissue from a previous surgery or biopsy needs to be sent to the research laboratory, or that patients must undergo a new biopsy before enrolling. The tissue is used for detailed analyses that help researchers understand why some patients respond to treatment while others don't.
Some trials specifically enroll patients who are undergoing surgery or who need surgery as part of their treatment. This allows researchers to collect fresh tumor tissue at the time of enrollment. Other trials may bank tissue samples for future analysis as new testing methods become available.
Standard Laboratory Tests
Before enrolling in a clinical trial, patients typically need standard blood tests and other laboratory work to confirm that their major organs are functioning well enough to handle the experimental treatment. These tests check kidney function, liver function, blood cell counts, and other health markers. Trials have specific thresholds that must be met, such as minimum levels of certain blood cells or maximum levels of certain liver enzymes.
These requirements exist because some experimental treatments can affect organs like the liver or kidneys, or might lower blood cell counts. Starting with adequate organ function and healthy blood counts helps ensure patient safety during the trial.
Previous Treatment History Documentation
Clinical trials carefully track what treatments patients have received before joining the study. Some trials only accept newly diagnosed patients who haven't yet received treatment beyond initial surgery. Other trials specifically enroll patients whose tumors have progressed despite previous treatment. Complete records of prior surgeries, radiation therapy, and chemotherapy are needed for trial enrollment.
This information is essential because previous treatments can affect how tumors respond to new therapies. It also helps researchers analyze results and determine which patients benefit most from experimental treatments. Accurate documentation of treatment history ensures that trial results can be properly interpreted.
Prognosis and Survival Rate
Prognosis
The prognosis for malignant gliomas varies depending on several factors, including the specific type of tumor, its grade, the patient's age, and how much of the tumor can be surgically removed. Malignant gliomas are considered among the most serious types of brain tumors, with glioblastomas being particularly aggressive. The disease progresses rapidly, and tumors tend to grow into surrounding healthy brain tissue, making complete removal difficult.
Patients who undergo complete or near-complete surgical removal of the tumor generally have better outcomes than those who can only have partial removal. After surgery, treatment with radiation therapy and chemotherapy has been shown to improve survival compared to surgery alone. Younger patients and those with better overall health and functional status tend to have better prognoses. Certain molecular features of the tumor also affect prognosis. For instance, tumors with IDH gene mutations generally have a better outlook than those without these mutations.
The peak incidence of malignant gliomas occurs between the fifth and sixth decades of life. Specifically, the median age at diagnosis for glioblastoma is 64 years, while for anaplastic gliomas it is 45 years. These tumors are approximately 40% more common in men than in women and occur twice as frequently in white populations compared to black populations.
Survival rate
Survival rates for malignant gliomas depend heavily on the tumor type and grade. For glioblastoma, which is the most aggressive form, median survival ranges from 9 to 12 months despite maximum treatment efforts. This statistic has changed little over several decades despite technological advances in surgery, radiation, and chemotherapy.
The five-year survival rate for glioblastomas remains very low, ranging from 5% to 13%. However, advances in treatment approaches have shown some improvement. Treatment with radiation therapy followed by chemotherapy with temozolomide has been shown to extend survival. Adding tumor-treating fields to standard treatment has extended life expectancy by an average of 4.9 months, while carmustine wafers have added approximately 2.3 months to survival.
For other types of malignant gliomas, such as anaplastic astrocytomas and anaplastic oligodendrogliomas, survival tends to be somewhat longer than for glioblastoma, though these remain serious conditions. Approximately one-quarter of patients with glioblastoma benefit from adjuvant chemotherapy, while the majority of patients with anaplastic astrocytoma show improvement with chemotherapy treatment. However, there is currently no reliable way to predict in advance which individual patients will respond best to chemotherapy.
